Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA First-Generic Notification Policy May Be Reviewed

Executive Summary

FDA will re-examine whether it is legally barred from notifying a generic company early in the ANDA process that it is the first filer eligible for 180-day exclusivity, Chief Counsel Dan Troy said Sept. 30
Advertisement

Related Content

Generic Exclusivity? Who Cares! Industry Offers Few Opinions On Potential Changes
Generic Exclusivity? Who Cares! Industry Offers Few Opinions On Potential Changes
U.S. Generic Exclusivity Process To Go Public?
Generic Exclusivity Awards Process Might Go Public
Paragraph IV Gets A Date: FDA Will Announce When ANDAs Are Submitted
Paragraph IV Gets A Date: FDA Will Announce When ANDAs Are Submitted
Medicare Bill Retains ANDA “Antibundling” Language “Livable” To GPhA
Generic Firms Break Camp; FDA Says “First-To-File” Covers Same-Day ANDAs
Generic Firms Break Camp; FDA Says “First-To-File” Covers Same-Day ANDAs
Advertisement
UsernamePublicRestriction

Register

PS042566

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel